EPISODE · Aug 4, 2026 · 35 MIN
The FDA Peptide Hearing
from Midlife Clarity with Dr. Tracy Page: Hormones, Menopause, Metabolism, and Strength for Women Over 40 · host Dr. Tracy Page
On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee considered seven peptide-related bulk drug substances for possible inclusion on the 503A Bulks List. Six received a favorable recommendation; one did not.That vote did not approve these peptides, and it did not immediately change their legal status. Advisory committees provide nonbinding recommendations. The FDA must still decide what action, if any, to take.In this episode, Dr. Tracy Page separates the facts from the headlines and explains what the hearing means for people who currently use peptides, are considering them, or simply want to understand the difference between regulated access and proven medical evidence.What You’ll Learn by ListeningWhat the Pharmacy Compounding Advisory Committee actually voted on — and why the vote was not an FDA approval.What the 503A Bulks List is, in plain English, and how it affects the ingredients that may be used by licensed compounding pharmacies.Which six peptides received favorable recommendations: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax.Why emideltide, also known as DSIP, was the only peptide that did not receive a favorable recommendation.Why the close vote counts reflect a divided committee rather than broad scientific agreement.The honest debate between expanding access through licensed pharmacies and requiring stronger human evidence before broader use.What FDA reviewers raised about the limited human research behind BPC-157, TB-500, KPV, and MOTS-c.Why encouraging laboratory and animal findings are not the same as well-designed human clinical trials.What changes — and what does not — if you are already following a physician-supervised peptide protocol.Why patients should not change treatment or purchase a peptide online because of a headline.How to confirm that a peptide is prescribed by a qualified clinician and sourced through a legitimate pharmacy.Why competitive and drug-tested athletes must consider their sport’s rules separately from medical prescribing rules.Why protein, sleep, movement, hormone health, and key nutrients remain foundational to recovery and repair, regardless of the regulatory outcome.The Most Important TakeawayNothing changed overnight. The committee’s vote was one step in a longer regulatory process. Patients should remain medically supervised, verify where their medication is coming from, avoid unregulated online products, and continue focusing on the foundations that support healing.Patient Resources and Relevant LinksOfficial FDA meeting page, agenda, and briefing materialsFDA: Bulk Drug Substances Used in Compounding Under Section 503AFDA: Consumer and Health Care Professional Information on Compounded DrugsWorld Anti-Doping Agency: 2026 Prohibited ListMidlife Clarity Podcast LibraryEpisode 15: TB-500 — The Peptide That Finds Your Injury & Heals ItEpisode 11: BPC-157 — The Body’s Own Repair CodeLearn More About Peptide Therapy at WIFMMedical DisclaimerThis episode is for educational purposes only and is not medical advice. An FDA advisory committee recommendation is not FDA approval. Compounded medications are not reviewed and approved by the FDA in the same manner as FDA-approved drugs. Do not begin, stop, or change a peptide protocol without speaking with your prescribing clinician. *********************Midlife Clarity with Dr. Tracy Page is a podcast for women over 40 navigating hormones, metabolism, strength, and healthy aging during midlife, perimenopause, and menopause.Connect with Dr. Page:Dr. Tracy Instagram: https://www.instagram.com/tracypagemd/Dr. Tracy Facebook: https://www.facebook.com/drtracypage/Connect with The Wisconsin Institute of Functional Medicine (WIFM):Website: Wisconsin Institute of Functional Medicine (WIFM) https://wisconsinfunctionalmed.com/WIFM Instagram: https://www.instagram.com/wisconsinfunctionalmed/YouTube - Wisconsin Institute of Functional Medicine: https://www.youtube.com/channel/UC_oZu2b83V06C0szpKmUU9gDISCLAIMER: The information shared on this podcast is for educational purposes only and is not intended as medical advice. It does not replace a consultation with your own physician or qualified health care provider. Always seek professional medical guidance regarding your personal health concerns.© 2026 Dr. Tracy Page
Embed this episode
What this episode covers
On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee considered seven peptide-related bulk drug substances for possible inclusion on the 503A Bulks List. Six received a favorable recommendation; one did not. That vote did not approve these peptides, and it did not immediately change their legal status. Advisory committees provide nonbinding recommendations. The FDA must still decide what action, if any, to take. In this episode, Dr. Tracy Page separates the facts from the he...
Ready to play
The FDA Peptide Hearing
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.